ARPO - Aerpio Pharmaceuticals, Inc.
| Previous Close | 0.8297 |
| Open | 0.8150 |
| Bid | 0.8150 x 1200 |
| Ask | 0.8418 x 1100 |
| Day's Range | 0.8150 - 0.8451 |
| 52 Week Range | 0.7500 - 4.3000 |
| Volume | 23,406 |
| Avg. Volume | 179,674 |
| Market Cap | 33.209M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3070 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.67 |
- American City Business Journals•14 days ago
This Cincinnati stock gained 457% in the first half of 2019: SLIDESHOW
Getting acquired paid off for two local public companies that posted some of the top stock gains in the first half of the year. But the biggest stock jump came from a company that barely generates sales.
- Business Wire•last month
Aerpio Initiates Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle Glaucoma
Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced dosing of the first subject in a Phase 1b trial of a topical ocular formulation of AKB-9778 in development for treatment of primary open angle glaucoma (POAG). The primary endpoint of the trial is ocular safety and tolerability, with IOP lowering as the key pharmacodynamic endpoint. “POAG is characterized by increased IOP leading to optic nerve and neuroretina anomalies and progressive visual field defects,” said Kevin Peters, M.D., Chief Scientific Officer of Aerpio Pharmaceuticals.
GuruFocus.com•2 months agoWall Street Sees 3 Falling Knives Rebounding Within 52 Weeks
The following companies are falling knives since their share prices have declined more than 59% over the past year through May 13. Wall Street issued a recommendation rating of overweight to buy for all three stocks, increasing the likelihood of them outperforming the S&P 500 index within 52 weeks. Warning! GuruFocus has detected 5 Warning Signs with CLDX.
- Business Wire•2 months ago
Aerpio Reports First Quarter 2019 Financial Results and Provides Business Update
On Track to Initiate Phase 1b Clinical Trial of Topical Drop Formulation of AKB-9778 for Primary Open-Angle Glaucoma in the Second Quarter of 2019
- Business Wire•3 months ago
Aerpio Pharmaceuticals Presents Data Showing Potential of AKB-9778, a VE-PTP Inhibitor/Tie2 Activator, to Lower Intra-ocular Pressure in Human Subjects
Data presented during “The Role of the Tie2 Pathway in Ocular Disease” symposium at the Association for Research in Vision and Ophthalmology 2019 Annual Meeting
- Business Wire•3 months ago
Aerpio Pharmaceuticals to Present Data Demonstrating Role of VE-PTP in Conventional Outflow Homeostasis and the Potential of AKB-9778, a VE-PTP Inhibitor/Tie2 Activator, as a Treatment for Open-Angle Glaucoma
Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, will present data demonstrating the role of VE-PTP in the conventional outflow pathway and the potential of AKB-9778, a VE-PTP inhibitor and Tie2 activator, as a treatment for open-angle-glaucoma. The data are to be presented at The Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting on April 29 in Vancouver, British Columbia.
- Zacks•3 months ago
Aerpio Pharmaceuticals, Inc. (ARPO) Upgraded to Buy: What Does It Mean for the Stock?
Aerpio Pharmaceuticals, Inc. (ARPO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- Business Wire•3 months ago
Aerpio Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference
Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 11:20 a.m. Eastern Time in New York, NY. Dr. Hoffman will provide a corporate overview and business update.
- American City Business Journals•4 months ago
Greater Cincinnati pharma firm’s stock plummets
Shares dropped more than 70 percent March 18 after the company disclosed the results of a clinical trial.
- Business Wire•4 months ago
Aerpio Pharmaceuticals Announces Results From TIME-2b Study of AKB-9778 in Diabetic Retinopathy
Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced top-line results from the Company’s TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, AKB-9778, for patients with moderate to severe non-proliferative diabetic retinopathy (NPDR). Administration of AKB-9778 twice daily did not meet the study’s primary endpoint of the percentage of patients with an improvement of two or more steps in the study eye diabetic retinopathy severity score (DRSS) compared to placebo.
- GuruFocus.com•4 months ago
Aerpio Pharmaceuticals Inc (ARPO) Files 10-K for the Fiscal Year Ended on December 31, 2018
Aerpio Pharmaceuticals Inc is a biopharmaceutical company. Warning! GuruFocus has detected 2 Warning Signs with IRMD. For the last quarter Aerpio Pharmaceuticals Inc reported a revenue of $0.00 million, compared with the revenue of $0.00 million during the same period a year ago.
- Business Wire•4 months ago
Aerpio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Top-Line Results from the TIME-2b Clinical Trial Evaluating the Effect of AKB-9778 in Patients with Non-Proliferative Diabetic Retinopathy Expected in March 2019
- Business Wire•5 months ago
Aerpio Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Tuesday, March 5, 2019
Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced that its fourth quarter and full year 2018 financial results will be released before the market opens on Tuesday, March 5, 2019. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. EST to discuss the Company’s financial results and provide a general business update. The live webcast and a replay may be accessed by visiting Aerpio's website at http://ir.aerpio.com/.
- Zacks•6 months ago
Aerpio (ARPO) Jumps: Stock Rises 7.8%
Aerpio (ARPO) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
- Business Wire•6 months ago
Aerpio Pharmaceuticals Announces Completion of Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic Retinopathy
Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced the completion of patient dosing in the Company’s TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, AKB-9778, for patients with moderate to severe non-proliferative diabetic retinopathy (NPDR). "We are pleased to announce completion of patient dosing in our 48-week Phase 2b trial, TIME-2b,” said Stephen Hoffman, M.D., Ph.D., Chief Executive Officer of Aerpio. AKB-9778 is our first-in-class, systemically-administered Tie2 activator in development for the treatment of diabetic retinopathy, as well as complications of diabetes and other ocular diseases.
- American City Business Journals•8 months ago
Cincinnati stocks soar as Dow Jones posts one of its five biggest gains ever
The stock market soared Wednesday with the Dow Jones Industrial Average posting its fifth-biggest point gain ever.
- GlobeNewswire•8 months ago
Recent Analysis Shows Atlas Financial, Royal Dutch Shell, Vaalco Energy, Myovant Sciences, Aerpio Pharmaceuticals, and Wheeler Real Estate Investment Trust Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Nov. 14, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Business Wire•8 months ago
Aerpio Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference
Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the Stifel 2018 Healthcare Conference on Wednesday, November 14, 2018 at 8:00 a.m. Eastern Time in New York, NY. Dr. Hoffman will provide a corporate overview and business update.
- Business Wire•8 months ago
Aerpio Reports Third Quarter 2018 Financial Results and Provides Business Update
TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy On Track
- Business Wire•9 months ago
Aerpio Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Wednesday, November 7, 2018
Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced that its third quarter 2018 financial results will be released before the market opens on Wednesday, November 7, 2018. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. EST to discuss the Company’s financial results and provide a general business update. The live webcast and a replay may be accessed by visiting Aerpio's website at http://ir.aerpio.com/.
- Business Wire•9 months ago
Aerpio Pharmaceuticals Announces Presentation of Renal Function Data from TIME-2 Study of AKB-9778 in Diabetic Retinopathy Patients at American Society of Nephrology Kidney Week 2018
Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that the Company will present renal function data obtained from the TIME-2 Phase 2 clinical trial of AKB-9778 in diabetic retinopathy patients at the American Society of Nephrology (ASN) Kidney Week 2018, Oct. 23-28, in San Diego. “VE-PTP, an inhibitor of Tie2, is expressed in the kidney and may be upregulated in patients with diabetes,” said Kevin Peters, M.D., chief scientific officer of Aerpio Pharmaceuticals.
- Business Wire•10 months ago
Aerpio Pharmaceuticals to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference
Aerpio Pharmaceuticals, Inc. , a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the Cantor Fitzgerald 2018 Global Healthcare Conference on Monday, October 1, 2018 at 10:40 a.m.
- Business Wire•11 months ago
Aerpio Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC
Aerpio Pharmaceuticals, Inc. , a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C.
- Benzinga•11 months ago
The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 15) Inspire Medical Systems Inc (NYSE: INSP ) Merck & Co., Inc. ...
